Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: T-cell acute lymphoblastic leukemias, Acute lymphoblastic leukemia, and Lymphoma.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 1 | Lymphoma |
90 clinical trials registered, 40 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 2 PHASE3, 26 PHASE2, 29 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05476770](https://clinicaltrials.gov/study/NCT05476770) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:42 AM UTC
Online Mendelian Inheritance in Man
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies |
PHASE1 |
Therapeutic Advances in Childhood Leukemia Consortium |
RECRUITING |
[NCT06131801](https://clinicaltrials.gov/study/NCT06131801) | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | — | Children's Hospital Medical Center, Cincinnati | RECRUITING |
[NCT06326463](https://clinicaltrials.gov/study/NCT06326463) | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | PHASE1 | St. Jude Children's Research Hospital | RECRUITING |
[NCT04747912](https://clinicaltrials.gov/study/NCT04747912) | Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | PHASE2 | University of Chicago | RECRUITING |
[NCT05043571](https://clinicaltrials.gov/study/NCT05043571) | CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | PHASE1 | National University Hospital, Singapore | RECRUITING |
19 publications have been identified in PubMed for lymphoblastic leukemia, acute, with lymphomatous features. Research spans Review / Meta-Analysis (26%), Clinical Trial Publication (26%), and Epidemiology / Natural History (21%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 5 | 26% |
Clinical study results | 5 | 26% |
Disease patterns and progression | 4 | 21% |
Laboratory research | 3 | 16% |
Patient case studies | 1 | 5% |
New treatment approaches | 1 | 5% |
Bender JD (2026). [PMID: 41889289](https://pubmed.ncbi.nlm.nih.gov/41889289/). *Pediatric blood & cancer*. [Clinical Trial Publication]
Jang HJ (2026). [PMID: 41824855](https://pubmed.ncbi.nlm.nih.gov/41824855/). *Medicine*. [Review / Meta-Analysis]
Mostafa M (2026). [PMID: 41562928](https://pubmed.ncbi.nlm.nih.gov/41562928/). *Medical sciences (Basel, Switzerland)*. [Review / Meta-Analysis]
Sharma S (2026). [PMID: 41843828](https://pubmed.ncbi.nlm.nih.gov/41843828/). *JMIR Res Protoc*. [Basic Science / Preclinical]
Peng JM (2025). [PMID: 40507267](https://pubmed.ncbi.nlm.nih.gov/40507267/). *Cancers*. [Review / Meta-Analysis]
Ansarian MA (2025). [PMID: 40277761](https://pubmed.ncbi.nlm.nih.gov/40277761/). *Current oncology (Toronto, Ont.)*. [Review / Meta-Analysis]
Perales MA (2025). [PMID: 40249911](https://pubmed.ncbi.nlm.nih.gov/40249911/). *Blood advances*. [Epidemiology / Natural History]
Lee JJ (2025). [PMID: 40043847](https://pubmed.ncbi.nlm.nih.gov/40043847/). *Transplantation and cellular therapy*. [Clinical Trial Publication]
Okada N (2025). [PMID: 39638286](https://pubmed.ncbi.nlm.nih.gov/39638286/). *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. [Epidemiology / Natural History]
Saultz JN (2025). [PMID: 41397550](https://pubmed.ncbi.nlm.nih.gov/41397550/). *Transplantation and cellular therapy*. [Clinical Trial Publication]